The University of Wits resumed vaccination of participants in the Oxford Covid-19 vaccine trial after receiving soft green from the South African Health Products Regulatory Authority and two ethics committees. The VIDA trial of the Ox1Cov-19 vaccine is the first in Africa and one of 268 candidate vaccines sought and tested worldwide. Following the announcement of the trial, Shabir Madhi, a professor of vaccination at the University of Wits and director of the Infectious Diseases and Vaccine Analysis Research Unit of the South African Medical Research Council and who leads the trial, said: this level of the Covid-19 pandemic. “South Africa has recently shown 655,572 cases of Covid-19, of which 15,772 were fatal and 585,303 resulted in cures.
Africa has the ability to mass produce COVID-19 vaccines if they are to be obtained next year, but the region will want to be more concerned in its research, writes Jackie . . . More information “
Gauteng overcame Western Cape as the epicenter of the COVID-19 epidemic in South Africa. In addition, gauteng’s Ministry of Health has demonstrated that six members of its COVID-19Array . . . Read more “
The South African vida Ox1Cov-19 vaccine trial developed through researchers from the University of Wits is the first in Africa and one of the 268 other candidate vaccines to be found in andArray lately. More information “
(File photo).
Almost finished. . .
We want to verify your email address.
To complete the process, please send the email commands we just sent you.
There is a challenge in processing your shipment. Come back later.